Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 22,258 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions: Attention control, Intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colorectal Cancer, Colorectal Cancer Stage I
Interventions: E-learning module; Other
Lead sponsor: Althaia Xarxa Assistencial Universitària de Manresa; Other
Eligibility: 28 Years and older
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Coronary Artery Disease
Interventions: TAXUS Liberté Paclitaxel-Eluting Coronary Stent, prasugrel, placebo, aspirin; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 82
States / cities: Mesa, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 72 more

Conditions: Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
Interventions: Tcelna, Placebo; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more

Conditions: Obesity
Interventions: Deposit Contract; Behavioral
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, t:slim X2 with Basal-IQ & Dexcom G6 CGM; Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Mucositis, Neoplasms
Interventions: Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse; Drug
Lead sponsor: Oral Defense, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Asthma in Children, Sleep Hygiene, Sleep, Inadequate
Interventions: Shortened Sleep, Stabilized sleep; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 7 Years to 11 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Glaucoma
Interventions: AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 18
States / cities: Inglewood, California • Petaluma, California • Poway, California + 15 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Teriflunomide, Evobrutinib; Drug
Lead sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 38
States / cities: Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more

Conditions: Emotional Regulation
Interventions: Mightier Family Games, Mightier online gameplay; Behavioral
Lead sponsor: Neuromotion Labs; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Treatment Adherence
Interventions: HT Helper app use plus patient navigation support, Patient Navigation support alone, Usual Care; Behavioral · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Female only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Multiple Sclerosis, Adult Disease
Interventions: Home-based exercise, Education, Exercise plus Education; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 50 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Postoperative Ileus, Colon Cancer, Pain, Postoperative, Postoperative Nausea and Vomiting
Interventions: Acupuncture, Sham Acupuncture; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19
Interventions: Lactobacillus Plantarum 299v Freeze Dried Capsule, Freeze Dried Potato Starch Capsule; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 89 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Bipolar Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Subjects
Interventions: E5555; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: DENV-3 Controlled Human Infection Model
Interventions: AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo; Drug
Lead sponsor: AbViro LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Anaplastic Astrocytoma, Glioblastoma
Interventions: trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System, carmustine, lomustine; Drug · Device · Procedure
Lead sponsor: Isarna Therapeutics GmbH; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Edison, New Jersey • Mineola, New York • Rochester, New York

Conditions: Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions: Placebo, PF-06865571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Anaheim, California • New Haven, Connecticut • South Miami, Florida + 3 more

Conditions: Obesity, Weight Loss
Interventions: Weight Stable Group; Behavioral
Lead sponsor: Wake Forest University; Other
Eligibility: 65 Years to 79 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Stroke, Balance; Distorted
Interventions: Body weight support system control group, Body weight support system with balance perturbations; Device
Lead sponsor: Gaylord Hospital, Inc; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Wallingford, Connecticut

Conditions: Alopecia Areata, Scarring Alopecia
Interventions: tSVF by lipoaspiration, PRP Concentration, Emulsification tSVF, cSVF isolation and concentration, cSVF in Normal Saline IV; Procedure
Lead sponsor: Regeneris Medical; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Irvine, California • North Attleboro, Massachusetts • Stevensville, Montana

Conditions: Encephalitis
Interventions: Valacyclovir, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 10 more

Search by objective public record fields.

Enhancing Adherence in Type 2 Diabetes: The ENHANCE Study

Web-based Learning Module on Optical Diagnosis of Early Colorectal Cancer

TAXUS Libertē Post Approval Study

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Brigham and Women's Healthy Weight Study

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)

Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis

Impact of Sleep Duration on Immune Balance in Urban Children With Asthma

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

Examining the Impacts of Parent-Child Interactive Activities

mHealth to Improve Medication Adherence Among Latina Breast Cancer Patients Experiencing Non-Medical Drivers of Health

Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior

Trial of Acupuncture for Reduction of Post-Colectomy Ileus

Impact of Lp299v on Vascular Function in Patients With PASC

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Effect of High Protein Weight Loss for Seniors

Explorations of the Benefits of the ZeroG TRiP System to Improve Balance in Patients Following Stroke

Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata

Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir